Novartis’s Itvisma Wins FDA Approval as First Gene Therapy for SMA

Novartis AG (NYSE: NVS) announced that Itvisma (onasemnogene abeparvovec‑brve) received U.S. FDA approval for children aged two and older, teens, and adults with Spinal Muscular Atrophy (SMA) caused by SMN1 gene mutations, becoming the first and only gene replacement therapy for this broad population.

Regulatory Milestone

Drug Profile

• Mechanism: Delivers functional copy of human SMN1 gene via adeno-associated viral vector
• Innovation: Addresses genetic root cause of SMA rather than symptoms
• Differentiation: First gene therapy approved for pediatric, adolescent, and adult SMA patients
• Dosing: Single intrathecal injection for sustained SMN protein expression

Clinical Evidence

Market Impact & Outlook

• Reimbursement: FDA approval triggers URAC discussions; value-based agreements likely given one-time nature
• Manufacturing: Utilizes existing AveXis gene therapy platform capacity
• Pipeline Expansion: Platform applicable to other neurological monogenic disorders

Forward-Looking Statements
This brief contains forward-looking statements regarding Itvisma’s commercial performance, market penetration, and manufacturing capacity. Actual results may differ materially due to risks including pricing negotiations, competitive responses, and real-world efficacy data.-Fineline Info & Tech